{"id":"W3025905658","doi":"10.1016/j.clcc.2020.04.008","title":"Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)","year":2020,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Institute of Cancer Research; Bayer HealthCare; Institut National Du Cancer; Institut Bergonié; Direction Générale de l’offre de Soins; Institut National de la Santé et de la Recherche Médicale","keywords":"Medicine; Irinotecan; Internal medicine; Bevacizumab; Oxaliplatin; Colorectal cancer; Sorafenib; Clinical endpoint; Progression-free survival; Gastroenterology; Oncology; Phases of clinical research; Randomized controlled trial; Cancer; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007873813,0.0007088003,0.003133602,0.0002103162,0.0001748293,0.00007245562,0.0002441884,0.0002173466,0.0007248344],"category_scores_gemma":[0.001489894,0.0005191806,0.0005020039,0.0009784983,0.0005960151,0.0002079265,0.0001417592,0.0007652955,0.00002471204],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001579538,"about_ca_system_score_gemma":0.00120681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006957381,"about_ca_topic_score_gemma":0.001832481,"domain_scores_codex":[0.9947314,0.0005788504,0.001759331,0.001193521,0.0009753487,0.0007614944],"domain_scores_gemma":[0.9966448,0.00099816,0.0006357168,0.0002568879,0.0007549937,0.0007094527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9504188,0.004785912,0.02732341,0.0001324772,0.001722023,0.00007280857,0.0026501,0.00005168541,0.0001303074,0.00001022297,0.001116564,0.01158575],"study_design_scores_gemma":[0.9172922,0.04410675,0.03269535,0.0003301311,0.001053836,7.342434e-7,0.00027152,0.001182296,0.000972675,0.00002165991,0.001458987,0.0006138215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9809287,0.0008548133,0.0000592703,0.004451718,0.001248425,0.01164522,0.000370967,0.0001851191,0.0002557829],"genre_scores_gemma":[0.9930547,0.0005895049,0.0002285826,0.00249533,0.0002878119,0.002934477,0.0001931752,0.0001129942,0.0001034115],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03932084,"threshold_uncertainty_score":0.999726,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04469850566048605,"score_gpt":0.3826672767687627,"score_spread":0.3379687711082766,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}